![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Endocrinology of Aging
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1534516
This article is part of the Research Topic Digital Technology in the Management and Prevention of Diabetes: Volume II View all 8 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Elderly type 2 diabetes mellitus (T2DM) patients complicated with heart failure (HF) exhibit a high rate of 30-day readmission. Predictive models have been suggested as tools for identifying high-risk patients. Thus, we aimed to develop and validate a predictive model using multicenter electronic medical records (EMRs) data to estimate the risk of 30-day readmission in elderly T2DM patients complicated with HF.Methods: EMRs data of elderly T2DM patients complicated with HF from five tertiary hospitals, spanning 2012 to 2023, were utilized to develop and validate the 30-day readmission model. The model were evaluated using holdout data with the area under the receiver operating characteristic curve (AUROC), calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC).Results: A total of 1899 patients were included, with 955, 409, and 535 in the derivation, internal validation, and external validation cohorts, respectively. Pulmonary infections (odds ratio [OR]: 3.816, 95% confidence interval [CI]: 2.377-6.128, P < 0.001), anti-hypertensive drug use (OR: 5.536, 95% CI: 1.658-18.486, P = 0.005), and neutrophil percentage-to-albumin ratio (NPAR) (OR: 1.144, 95% CI: 1.093-1.197, P < 0.001) were independent predictors of 30-day readmission risk. AUROC in the derivation, internal validation, and external validation cohorts were 0.782 (95% CI: 0.737-0.826), 0.746 (95% CI: 0.654-0.838), and 0.753 (95% CI: 0.684-0.813), respectively. The calibration curve, DCA results, and CIC results indicated that the model also possessed good predictive power. Additionally, an operation interface on a web page (https://cqykdxtjt.shinyapps.io/readmission/) was created for clinical practitioners to apply.: A 30-day readmission risk prediction model was developed and externally validated. This model facilitates the targeting of interventions for elderly T2DM patients complicated with HF who are at high risk of an early readmission.
Keywords: type 2 diabetes mellitus, Heart Failure, 30-day readmission, Prediction model, Electronic Medical Records
Received: 26 Nov 2024; Accepted: 12 Feb 2025.
Copyright: © 2025 He, Yuan, Tan, Zhang, Liu and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qingzhu Tan, Medical records and statistics room, Affiliated Banan Hospital of Chongqing Medical University, Chongqing, China
Xiao Zhang, Medical records and statistics room, Affiliated Banan Hospital of Chongqing Medical University, Chongqing, China
Minglun Xiao, Department of Gerontology, Affiliated Banan Hospital of Chongqing Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.